

Remarks

The specification, and Claims 39 and 41 have been amended to recite a reference to the SEQ ID NO. No new matter has been added.

Please replace the specification with the attached substitute specification. The substitute specification includes no new matter.


The Communication states that a sequence identifier is missing from page 3, lines 19-20. Applicants respectfully submit that PIKL is an acronym for "phosphatidyl inositol 3-kinase like", and is not a peptide sequence. The other sequences noted by the Examiner have been identified with a SEQ ID number. No new sequences have been added to the SEQLIST, and therefore the previously filed sequence listing is still correct.

Applicants submit that all of the claims are in condition for allowance, which action is requested. If the Examiner finds that a Telephone Conference would expedite the prosecution of this application, she is invited to telephone the undersigned at the number provided.

The Commissioner is hereby authorized to charge any other fees under 37 C.F.R. §§ 1.16 and 1.17 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 50-0815, order number MEWE-014.

Respectfully submitted,

Date: December 17, 2004

By: 
Pamela J. Sherwood, Ph.D.
Registration No. 36,677

BOZICEVIC, FIELD & FRANCIS LLP
1900 University Avenue, Suite 200
East Palo Alto, CA 94303
Telephone: (650) 327-3400
Facsimile: (650) 327-3231